Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Turnstone Biologics Corp. (NASDAQ:TSBX) stock is trading lower after the company released initial data from its Phase 1 STARLING trial of TIDAL-01 in metastatic microsatellite-stable colorectal cancer (MSS mCRC) on Thursday.
TIDAL-01 is a tumor-infiltrating lymphocyte therapy. In cancer therapy, tumor-infiltrating lymphocytes are removed from a patient’s tumor, grown in large numbers in a laboratory, and then given back to the patient to help the immune system kill the cancer cells.
As of the cutoff date of July 15, 2024, key takeaways from the initial data include the following:
In a second-quarter earnings release, Turnstone said its clinical development strategy for TIDAL-01 is now focused on “three high unmet medical need indications, including colorectal cancer, head and neck cancer, and uveal melanoma.”
The trial is currently enrolling patients with colorectal cancer, head and neck squamous cell carcinoma, and uveal melanoma. The company has deprioritized cutaneous melanoma and breast cancer.
As of June 30, 2024, cash, cash equivalents and short-term investments were $62.4 million. The company expects the combined cash, cash equivalents and short-term investments will be sufficient to fund its operations into the third quarter of 2025.
TSBX Price Action: Turnstone Biologics stock is down 57.53% at 93 cents at publication Thursday.
Read Next:
Photo: Shutterstock
Posted In: TSBX